Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- 28 November 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 388 (10063), 2997-3005
- https://doi.org/10.1016/s0140-6736(16)32389-3
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsCell Reports, 2013
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's ExperienceThe Oncologist, 2013
- Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyBreast Cancer Research and Treatment, 2012
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJournal of Clinical Oncology, 2009
- A recycling framework for the construction of Bonferroni‐based multiple testsStatistics in Medicine, 2009
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2008
- Analysis of duration of response in oncology trialsContemporary Clinical Trials, 2008
- Fulvestrant (Faslodex®)—How to Make a Good Drug BetterThe Oncologist, 2007
- Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2003